Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)

Publication date: 2016 Source:Breast Diseases: A Year Book Quarterly, Volume 27, Issue 2 Author(s): A.B. Tabchy
Source: Breast Diseases: A Year Book Quarterly - Category: Cancer & Oncology Source Type: research